Clinical Trial Update: A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease [Phase 4]

View source ↗

Summary

Clinical trial update for Teprotumumab N01 in active thyroid eye disease is listed as Phase 4 and not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Eye Disease

Drugs mentioned

• TEPEZZA (teprotumumab)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Thyroid Eye Disease | Phase 4 | Status: NOT_YET_RECRUITING